- Today
- 8 years of data protection plus 2 years of market protection, with 1 extra year for a significant new indication.
- New rules
- 8 years of data protection plus 1 year of market protection (Directive Art 83). Market protection is extended by 12 months, once, if the medicine addresses an unmet medical need, or if a medicine with a new active substance meets one of three sets of conditions: a comparator trial in line with EMA scientific advice and filing in the EU first or within 90 days of the first filing outside the EU; a comparator trial and efficacy trials in more than one Member State; or, where a comparator trial is not possible, efficacy trials in more than one Member State and that early EU filing (Art 84(1)). One more year of market protection if a new indication with significant clinical benefit is authorised during data protection, granted once (Art 84(2)). Market protection cannot run more than 2 years past the end of data protection, or 3 with the new-indication year (Art 84(3)): at most 11 years in total, or 12 if an antimicrobial voucher adds a year of data protection. Applications submitted before 24 months after entry into force keep the old periods (Art 221(5)).
- What it means
- The baseline drops from 10 to 9 years. Getting back to 10 or 11 years depends on choices made during development and filing: comparator trials, where trials run, and how soon you file in the EU.
- Next step
- Map each asset against the extension routes now; they shape trial design and filing strategy.
Status Agreed text, not yet in force
Area Exclusivity & IP
Relevant to Biotech / originator, Authorised in the EU, In development
SourceDirective, Council position at first reading (ST 7106/26), Articles 83, 84, 85 and 221(5)Open text: source for Regulatory protection is reshuffled (PDF)
Last verified21 November 2026 · AI-assisted check against the official text, pending human legal review
Still to verify (1)
- Needs source: the current rules ('Today') are in Directive 2001/83/EC, Article 10, which has not been checked against the official text yet.